Immunic is trading at $7.84, up 5.80%, amid a broader biotech rally; no direct link to the move was stated. - Immunic announced new vidofludimus calcium clinical, biomarker and preclinical data across four presentations at MSToronto2026 on October 21, highlighting Phase 2 extension findings and other analyses. - XBI was reported up 2.10%, with sector strength associated with M&A activity and positive clinical-trial news. No trading-volume information was available.